In a successful pre-clinical study on pancreatic cancer – the second most lethal form of the disease that is profoundly resistant to chemo and immunotherapy – researchers from the Leiden University Medical Center (LUMC) discovered a surprising new role for SUMO proteins in tumour immunology.
Testing novel therapeutics for the treatment of pancreatic cancer, Alfred Vertegaal, professor of Cell Biology, Sumit Kumar, postdoctoral fellow at the LUMC department of Cell and Chemical Biology and colleagues have set the stage for Small Ubiquitin-like Modifiers (SUMOs) research in tumour immunology. Their findings have been published in Gut.
Read more on LUMC.nl.
Looking for information on one of our topics, a new place to conduct your research or experienced research to join forces with? Feel free to contact us.!